---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-023887"
form_type: "8-K"
ticker: "TERN"
cik: "0001831363"
company_name: "Terns Pharmaceuticals, Inc."
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T01:52:55.832731+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Terns Pharma Q3 net loss $16.8M; cash $187M; pipeline on track for 2023 trials

## Summary
- Net loss of $16.8M for Q3 2022 ($0.44 per share), compared to $11.8M ($0.47) in Q3 2021.
- Cash, cash equivalents and marketable securities totaled $187.3M at Sept 30, 2022, providing runway into 2025.
- R&D expenses rose to $12.2M (Q3 2022) from $7.2M (Q3 2021); G&A expenses were $5.1M vs $4.7M.
- Plan to initiate U.S. Phase 1 trial for TERN-701 (allosteric BCR-ABL) in CML in H2 2023; top-line DUET data for TERN-501 expected H2 2023.
- IND-enabling activities for TERN-601 (oral GLP-1R) on track; first-in-human obesity trial planned in 2023.

## SEC filing metadata
- accession: 0000950170-22-023887
- form_type: 8-K
- ticker: TERN
- cik: 0001831363
- company_name: Terns Pharmaceuticals, Inc.
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831363/000095017022023887/0000950170-22-023887-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831363/000095017022023887/tern-20221109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-023887
- JSON: https://secwatch.observer/filing/0000950170-22-023887.json
- Plain text: https://secwatch.observer/filing/0000950170-22-023887.txt

## Key facts
- Earnings Releases
  Terns Pharmaceuticals, Inc. reported financial results for three and nine months ended September 30, 2022.
  - Period: three and nine months ended September 30, 2022
  - Result: reported results
  source text: On November 9, 2022, Terns Pharmaceuticals, Inc. issued a press release announcing its financial results for the three and nine months ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831363/000095017022023887/0000950170-22-023887-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.